- Brand names:
- Pharmaceutical Company:
- Condition/Indication: Human immunodeficiency virus infection
- Meeting Date: November 2022
- Public Summary Document (PSD) November 2022 PBAC Meeting - (PDF 1.6MB)
- Public Summary Document (PSD) November 2022 PBAC Meeting - (Word 1.9MB)
Lenacapavir – November 2022
Lenacapavir: Tablet 300 mg, Pack containing 2 injection sets 463.5 mg in 1.5 mL; Sunlenca®
Last updated
17 March 2023